PL366840A1 - Zastosowanie galantaminy do leczenia objawów chorobowych ośrodkowego układu nerwowego spowodowanychzatruciami substancjami psychotropowymi - Google Patents

Zastosowanie galantaminy do leczenia objawów chorobowych ośrodkowego układu nerwowego spowodowanychzatruciami substancjami psychotropowymi

Info

Publication number: PL366840A1
Authority: PL; Poland
Prior art keywords: galanthamine; psychotropic; treatment; central nervous; substances
Prior art date: 2001-04-24

Application number

PL02366840A

Other languages

English (en)

Other versions

PL207525B1 (pl

Inventor

Klaus Opitz

Joachim Moormann

Thomas Hille

Frank Becher

Original Assignee

Hf Arzneimittelforschung Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-24

Filing date

2002-04-18

Publication date

2005-02-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL366840(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-18 Application filed by Hf Arzneimittelforschung Gmbh filed Critical Hf Arzneimittelforschung Gmbh

2005-02-07 Publication of PL366840A1 publication Critical patent/PL366840A1/pl

2010-12-31 Publication of PL207525B1 publication Critical patent/PL207525B1/pl

Links

ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title abstract 4
230000000506 psychotropic effect Effects 0.000 title abstract 4
239000000126 substance Substances 0.000 title abstract 3
HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 title abstract 2
LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 title abstract 2
229960003980 galantamine Drugs 0.000 title abstract 2
BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 title abstract 2
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title abstract 2
IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 title abstract 2
210000003169 central nervous system Anatomy 0.000 title 1
230000035987 intoxication Effects 0.000 title 1
231100000566 intoxication Toxicity 0.000 title 1
230000007170 pathology Effects 0.000 title 1
239000003814 drug Substances 0.000 abstract 3
230000001684 chronic effect Effects 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
231100000614 poison Toxicity 0.000 abstract 2
230000002035 prolonged effect Effects 0.000 abstract 2
239000003440 toxic substance Substances 0.000 abstract 2
206010037180 Psychiatric symptoms Diseases 0.000 abstract 1
241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
231100000570 acute poisoning Toxicity 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000012458 free base Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000009032 substance abuse Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Addiction (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL366840A 2001-04-24 2002-04-18 Zastosowanie galantaminy do leczenia objawów chorobowych ośrodkowego układu nerwowego spowodowanych zatruciami substancjami psychotropowymi PL207525B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10119862A DE10119862A1 (de)	2001-04-24	2001-04-24	Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen

Publications (2)

Publication Number	Publication Date
PL366840A1 true PL366840A1 (pl)	2005-02-07
PL207525B1 PL207525B1 (pl)	2010-12-31

Family

ID=7682409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL366840A PL207525B1 (pl)	2001-04-24	2002-04-18	Zastosowanie galantaminy do leczenia objawów chorobowych ośrodkowego układu nerwowego spowodowanych zatruciami substancjami psychotropowymi

Country Status (26)

Country	Link
US (1)	US8207159B2 (pl)
EP (1)	EP1383507B1 (pl)
JP (1)	JP2004531533A (pl)
KR (1)	KR20040005934A (pl)
CN (1)	CN100400043C (pl)
AR (1)	AR033468A1 (pl)
AT (1)	ATE378052T1 (pl)
AU (1)	AU2002308148B2 (pl)
BR (1)	BR0209126A (pl)
CA (1)	CA2444818C (pl)
CZ (1)	CZ20032789A3 (pl)
DE (2)	DE10119862A1 (pl)
DK (1)	DK1383507T3 (pl)
EA (1)	EA200301135A1 (pl)
ES (1)	ES2296990T3 (pl)
HU (1)	HUP0401123A3 (pl)
IL (2)	IL158382A0 (pl)
MX (1)	MXPA03009765A (pl)
NO (1)	NO20034740L (pl)
NZ (1)	NZ529004A (pl)
PL (1)	PL207525B1 (pl)
PT (1)	PT1383507E (pl)
SK (1)	SK287235B6 (pl)
TW (1)	TWI329512B (pl)
WO (1)	WO2002085370A1 (pl)
ZA (1)	ZA200308004B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004216360B2 (en) *	2003-02-27	2009-09-17	Eisai R & D Management Co., Ltd.	Pharmaceutical composition for treatment of drug dependence
DE10338544B4 (de) *	2003-08-19	2017-08-31	Janssen Pharmaceutica N.V.	Buccale Formulierungen des Galanthamins und deren Anwendungen
FR2930891B1 (fr)	2008-05-06	2010-09-24	Biocodex	Composes anti-amnesiants et compositions pharmaceutiques les comprenant
EP2586436A1 (en)	2011-10-31	2013-05-01	Commissariat à l'Énergie Atomique et aux Énergies Alternatives	Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
AU2016264228B2 (en) *	2015-05-18	2019-06-13	Synaptec Development Llc	Galantamine clearance of amyloidß
EP4486448A1 (en)	2022-03-04	2025-01-08	Reset Pharmaceuticals, Inc.	Co-crystals or salts comprising psilocin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1193061B (de)	1961-12-20	1965-05-20	Vni Chimiko Pharmazewtitschesk	Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US3797494A (en)	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en)	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
US3742951A (en)	1971-08-09	1973-07-03	Alza Corp	Bandage for controlled release of vasodilators
US4031894A (en)	1975-12-08	1977-06-28	Alza Corporation	Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de)	1983-04-27	1986-03-27	Lohmann Gmbh & Co Kg, 5450 Neuwied	Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4666829A (en) *	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6150354A (en) *	1987-01-15	2000-11-21	Bonnie Davis	Compounds for the treatment of Alzheimer's disease
DE3843239C1 (pl)	1988-12-22	1990-02-22	Lohmann Therapie Syst Lts
US5015645A (en) *	1989-10-19	1991-05-14	Ciba-Geigy Corporation	Tetracyclic pyrrole lactam derivatives
US5519017A (en)	1990-03-29	1996-05-21	Lts Lohmann Therapie-Systeme Gmbh + Co. Kg	Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de)	1990-03-29	1991-10-02	Lohmann Therapie Syst Lts	Pharmazeutische formulierung zur behandlung des alkoholismus
US5336675A (en) *	1991-05-14	1994-08-09	Ernir Snorrason	Method of treating mania in humans
DE4301782C1 (de)	1993-01-23	1994-08-25	Lohmann Therapie Syst Lts	Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE19509663A1 (de)	1995-03-17	1996-09-19	Lohmann Therapie Syst Lts	Verfahren zur Isolierung von Galanthamin
WO1998007431A1 (en) *	1996-08-22	1998-02-26	New York University	Cholinesterase inhibitors for treatment of parkinson's disease
US5932557A (en) *	1997-08-12	1999-08-03	Mustafa; S. Jamal	Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
CN1240384C (zh) *	1999-11-04	2006-02-08	美国爱科赛尔制药有限公司	石杉碱经皮给药制剂
US20020151591A1 (en) *	2000-10-17	2002-10-17	Anabella Villalobos	Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders

2001
- 2001-04-24 DE DE10119862A patent/DE10119862A1/de not_active Withdrawn
2002
- 2002-04-18 ES ES02764017T patent/ES2296990T3/es not_active Expired - Lifetime
- 2002-04-18 CA CA002444818A patent/CA2444818C/en not_active Expired - Lifetime
- 2002-04-18 WO PCT/EP2002/004277 patent/WO2002085370A1/de not_active Ceased
- 2002-04-18 JP JP2002582943A patent/JP2004531533A/ja active Pending
- 2002-04-18 PT PT02764017T patent/PT1383507E/pt unknown
- 2002-04-18 DE DE50211207T patent/DE50211207D1/de not_active Expired - Lifetime
- 2002-04-18 EP EP02764017A patent/EP1383507B1/de not_active Expired - Lifetime
- 2002-04-18 CZ CZ20032789A patent/CZ20032789A3/cs unknown
- 2002-04-18 KR KR10-2003-7013971A patent/KR20040005934A/ko not_active Ceased
- 2002-04-18 SK SK1315-2003A patent/SK287235B6/sk not_active IP Right Cessation
- 2002-04-18 EA EA200301135A patent/EA200301135A1/ru unknown
- 2002-04-18 CN CNB028088905A patent/CN100400043C/zh not_active Expired - Lifetime
- 2002-04-18 MX MXPA03009765A patent/MXPA03009765A/es active IP Right Grant
- 2002-04-18 NZ NZ529004A patent/NZ529004A/en unknown
- 2002-04-18 HU HU0401123A patent/HUP0401123A3/hu unknown
- 2002-04-18 AU AU2002308148A patent/AU2002308148B2/en not_active Ceased
- 2002-04-18 IL IL15838202A patent/IL158382A0/xx unknown
- 2002-04-18 US US10/475,357 patent/US8207159B2/en not_active Expired - Fee Related
- 2002-04-18 AT AT02764017T patent/ATE378052T1/de active
- 2002-04-18 PL PL366840A patent/PL207525B1/pl not_active IP Right Cessation
- 2002-04-18 DK DK02764017T patent/DK1383507T3/da active
- 2002-04-18 BR BR0209126-7A patent/BR0209126A/pt not_active Application Discontinuation
- 2002-04-22 TW TW091108204A patent/TWI329512B/zh not_active IP Right Cessation
- 2002-04-24 AR ARP020101482A patent/AR033468A1/es unknown
2003
- 2003-10-13 IL IL158382A patent/IL158382A/en active IP Right Grant
- 2003-10-15 ZA ZA200308004A patent/ZA200308004B/en unknown
- 2003-10-23 NO NO20034740A patent/NO20034740L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL207525B1 (pl)	2010-12-31
HK1062401A1 (zh)	2004-11-05
ATE378052T1 (de)	2007-11-15
SK287235B6 (sk)	2010-04-07
KR20040005934A (ko)	2004-01-16
TWI329512B (en)	2010-09-01
NO20034740D0 (no)	2003-10-23
CZ20032789A3 (en)	2004-05-12
AR033468A1 (es)	2003-12-17
CN1505516A (zh)	2004-06-16
EA200301135A1 (ru)	2004-04-29
DE10119862A1 (de)	2002-11-07
EP1383507A1 (de)	2004-01-28
ES2296990T3 (es)	2008-05-01
HUP0401123A3 (en)	2008-01-28
ZA200308004B (en)	2004-02-11
IL158382A (en)	2009-09-01
DK1383507T3 (da)	2008-03-17
NO20034740L (no)	2003-10-23
SK13152003A3 (sk)	2004-04-06
BR0209126A (pt)	2004-07-27
IL158382A0 (en)	2004-05-12
MXPA03009765A (es)	2005-04-19
PT1383507E (pt)	2008-02-20
HUP0401123A2 (hu)	2004-09-28
EP1383507B1 (de)	2007-11-14
WO2002085370A1 (de)	2002-10-31
CA2444818C (en)	2009-06-16
CA2444818A1 (en)	2002-10-31
DE50211207D1 (de)	2007-12-27
JP2004531533A (ja)	2004-10-14
NZ529004A (en)	2007-01-26
CN100400043C (zh)	2008-07-09
US20040116406A1 (en)	2004-06-17
AU2002308148B2 (en)	2006-11-02
US8207159B2 (en)	2012-06-26

Legal Events

Date	Code	Title	Description
2013-06-28	LAPS	Decisions on the lapse of the protection rights	Effective date: 20120418

Publication	Publication Date	Title
GEP20084325B (en)	2008-03-25	Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands
PL373626A1 (pl)	2005-09-05	Leczenie zaburzeń centralnego układu nerwowego
PL375053A1 (pl)	2005-11-14	Agoniści receptora sfingozyno-1-fosforanu w leczeniu zaburzeń demielinizacyjnych
GB2333453A (en)	1999-07-28	Colostrinin and uses thereof
EP1551793A4 (en)	2007-04-04	TETRAFLUORBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF FOR THE PREVENTION AND TREATMENT OF ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES OF THE CENTRAL NERVOUS SYSTEM
PT1176963E (pt)	2005-05-31	Utilizacao de ligandos do receptor d3 da dopamina no fabrico de medicamentos para o tratamento de disturbios da funcao renal
TW200531680A (en)	2005-10-01	Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1900362A3 (en)	2009-04-01	Alfa-aminoamide derivatives useful in the treatment of addictive disorders
PL1824493T3 (pl)	2009-01-30	Zawiesina zawierająca meloksykam do podawania doustnego
IL158382A (en)	2009-09-01	Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances
WO2006074226A3 (en)	2006-11-16	Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof
CA2176298A1 (en)	1996-12-28	A single high dose fluoroquinolone treatment
MXPA04003717A (es)	2004-07-30	Tableta masticlabe que contiene lisina.
WO2004082584A3 (en)	2004-11-04	5ht2c receptor antagonists in the treatment of schizophrenia
FI3825306T3 (fi)	2023-08-23	Morfinaaniyhdisteitä
MY135676A (en)	2008-06-30	Use of deoxypeganine for the treatment of pathological manifestations of the central nervous system based on intoxication with psychotropic substances
DK1626973T3 (da)	2011-01-10	(1S,5S)-3-(5,6-dichlor-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptan med analgesisk virkning
WO2002071060A3 (en)	2003-10-30	Use of metabolic phenotyping in individualized treatment with amonafide
NO953892D0 (no)	1995-09-29	Imidazolokinoksalinon-derivater som EAA-antagonister
WO2002070499A3 (en)	2002-10-31	Prodrugs derivatives of the ascorbic acid suitable to the passage of the hematoencephalic barrier
EA200100802A1 (ru)	2002-04-25	Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
TW200503783A (en)	2005-02-01	Oral pharmaceutical preparation for proton pump antagonists
MY116362A (en)	2004-01-31	Use of selegiline for the treatment of epileptic disorders
BR0012758A (pt)	2002-04-02	Tablete detergente revestido
Gerspacher	2005	Selective and combined neurokinin receptor antagonists